![](https://endpts.com/wp-content/uploads/2022/11/Fred-Aslan-Artiva-tile.jpg)
Fred Aslan, Artiva Biotherapeutics CEO
Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline
Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated SEC …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.